Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab + nivolumab with induction chemoradiotherapy before surgery for resectable or borderline resectable locally advanced NSCLC
NL-OMON24908Recruiting
- Sponsor
- VU University Medical Center
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ipilimumab and nivolumab in non-small cell lung cancer (NSCLC), sponsored by VU University Medical Center. Primary endpoints: Safety of adding ipilimumab and nivolumab to induction chemoradiotherapy and Pathological tumor response. Started Mar 2020; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON24908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24908.